Trump's tariffs on drugmakers may harm trade

President Donald Trump's implementation of 100% tariffs on certain patented pharmaceutical products took effect, aiming to boost domestic drug manufacturing. Experts, however, warn that smaller and mid-sized drugmakers may be forced to close or merge, potentially reducing medication availability and raising prices, especially for patients relying on non-exempt medicines. Many larger companies and specific drug categories are exempt from these tariffs, limiting their overall impact. Industry leaders express concern that the tariffs could hinder innovation and slow the development of new drugs.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل